Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Post by gijo333on Mar 03, 2017 10:08am
140 Views
Post# 25926148

News release

News releaseAs investors we need to know the result of the first OxC sale! Without news I can only imagine the worse. That sale to Unahco propelled this stock to 21 cents. It was the single most important event for this company and the market confirmed that. To now take the position that this sale was no big deal and not be concerned with the outcome is Ostrich economics. The market has reacted and reduced the value of this company from nearly 60 million to 30 million. Now to pull off a consolidation at a time where there is obvious uncertainty in the market value of OxC is also ridiculous. To make this action worse it is being leveraged by an interim CEO that has blown off lots of his shares in the last months. I know I'm going to take a beating for stating these facts because so many Avivagen stock holders feel that if you ignore the incompetence it just goes away. I have not seen consolidation work in the best interest of share holders and for sure not in this particular case. 
Bullboard Posts